Publications by authors named "A Alip"

Claim this Profile
G
Guidelines for HER2 reporting in breast cancer: Recommendations by the Malaysian Breast Pathology Working Group.
G C Tan, A Alip, I C V Ho, M Mohamed, M Md Yusof

Malays J Pathol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira, Adlinda Alip

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira, Adlinda Alip

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline deletion: results of the phase II AUROR study.
Gwo Fuang Ho, Soo Chin Lee, Anita Zarina Bustam, Adlinda Alip, Nur Fadhlina Abdul Satar

Lancet Reg Health West Pac· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Byoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, Se-Hoon Lee, Pongwut Danchaivijitr, Adlinda Alip

Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis